Cardiorenal Syndrome for Better Health With Integrative Care

Find out how integrative care can bridge the gap between cardiac and renal health for patients dealing with cardiorenal syndrome.

Integrative Cardiorenal Care: A Modern Multidisciplinary Approach to Heart and Kidney Health

Hello, I’m Dr. Alexander Jimenez. With my credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), board-certified Family Nurse Practitioner (FNP-BC), and certifications in Functional Medicine (CFMP, IFMCP), Advanced Traditional Chinese Medicine (ATN), and Cranial-Sacral Therapy (CCST), I am dedicated to providing a comprehensive, integrative perspective on health.

Today, we will embark on an educational journey into the intricate relationship between the heart and kidneys, a condition known as cardiorenal syndrome (CRS). This condition, where dysfunction in one organ leads to dysfunction in the other, presents significant challenges for both patients and healthcare providers. We will explore the latest evidence-based diagnostic strategies and management techniques, drawing upon the work of leading researchers. This post will detail the physiological underpinnings of CRS, why certain tests are crucial, what their results signify, and how we can effectively assess a patient’s condition.

At our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic), we pride ourselves on a multidisciplinary, integrative model of care. I work alongside our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is board-certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933) and brings over 40 years of invaluable experience. Her medical oversight is a cornerstone of our practice, enabling us to seamlessly integrate chiropractic care, functional medicine, rehabilitation, and traditional medical management. This collaborative framework, common in integrative and injury-care clinics, ensures our patients in El Paso, Texas, receive a holistic and robust treatment plan tailored to their unique needs. Throughout this discussion, I will highlight how integrative chiropractic care plays a vital role within this comprehensive approach.

Abstract

In this educational post, I walk you through the modern understanding of cardiorenal syndrome—the dynamic and complex crosstalk between the heart and kidneys—using evidence-based, clinically grounded methods. You will learn how neurohormonal systems (renin-angiotensin-aldosterone system, sympathetic drive, and natriuretic peptides) orchestrate fluid and pressure regulation, why chronic activation becomes maladaptive, and how venous congestion, forward versus backward flow, inflammation, and oxidative stress accelerate organ dysfunction. I explain the physiological underpinnings, detail practical strategies such as physical assessment of congestion and diagnostic testing, and discuss tailored pharmacologic therapies, including diuretics and guideline-directed medical therapy. Throughout, I detail how our team at Injury Medical Clinic PA integrates chiropractic care, functional medicine, internal medicine oversight, and rehabilitation services to address heart-kidney dynamics as part of whole-person care.

Meet Our Collaborative Cardiorenal Team in El Paso

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, our patients benefit from a multidisciplinary, integrative model typical of modern injury and functional medicine clinics.

• Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine, serves as our Medical Director and Collaborative Physician. With over 40 years of experience as an internist, Dr. Cardenas provides medical oversight for complex cases, guides diagnostics, and supervises pharmacologic and medical protocols, ensuring evidence-based safety.
• My role integrates chiropractic care and functional medicine with advanced clinical assessment, rehabilitation, and personal injury care, co-managed under Dr. Cardenas’s medical oversight.
• Our shared goal: combine medical diagnostics, evidence-based pharmacology, functional medicine strategies, and integrative chiropractic care to optimize cardiometabolic health, reduce congestion, and support renal resilience.

This model allows us to translate cutting-edge research into practical steps for patients dealing with acute decompensated heart failure, cardiorenal syndrome, and congestive states—while accounting for musculoskeletal factors, autonomic balance, and lifestyle determinants that often get overlooked.

Understanding Cardiorenal Syndrome: The Heart-Kidney Crosstalk

In practice, I see cardiorenal syndrome as a tug-of-war between the right ventricle and the kidneys. Both organs are endocrine in function.

• The heart secretes natriuretic peptides: atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). These promote vasodilation, natriuresis, and fluid offloading.
• The kidneys and adrenal system drive the renin-angiotensin-aldosterone system (RAAS): renin, angiotensin I/II, and aldosterone. These support vasoconstriction, sodium retention, and water conservation.

In health, these systems balance each other. In heart failure, RAAS predominance and chronic sympathetic activation overwhelm the heart’s natriuretic signaling, leading to sustained fluid retention and elevated vascular tone. Clinically, this manifests as elevated filling pressures, congestion, and renal vulnerability.

Why Elevated BNP Is More Than “Fluid”

When we assess BNP or NT-proBNP, I remind patients and clinicians: these are endocrine signals, not merely “stretch markers.” As RAAS and sympathetic drive intensify, BNP rises like a TSH response in hypothyroidism—trying to counterbalance the dominant system. Yet over time, the kidney’s endocrine strength tends to win, tilting the balance towards vasoconstriction and retention.

Pathophysiology: From Compensation to Maladaptation

Heart failure can begin from multiple etiologies—ischemia, hypertension, valvular disease, cardiomyopathies, toxins, and more. Two immediate shifts occur:

• Decreased cardiac output due to reduced stroke volume and increased LV wall stress
• Increased preload, reflected by elevated left atrial pressure and central venous pressure

The body’s compensations mobilize quickly:

• RAAS activation: vasoconstriction to preserve perfusion pressure; aldosterone increases sodium and water retention
• Sympathetic nervous system (SNS) activation: increases heart rate to maintain cardiac output (CO = HR × SV), and triggers inflammatory cytokines

Short-term, these are adaptive. Chronic activation becomes maladaptive:

• Persistent vasoconstriction worsens cardiac performance, further activating RAAS
• Aldosterone-driven retention fuels edema—pulmonary, abdominal, peripheral
• Inflammatory cytokines and oxidative stress damage microstructures in the heart and kidney

This runaway loop underpins many clinical scenarios where diuresis becomes difficult, renal function declines, and congestion persists.

Forward Flow Versus Backward Flow: Reframing Cardiac Performance

Four decades ago, as heart transplant programs grew and right heart catheterizations became common, clinicians developed hemodynamic profiles and emphasized contractility as the primary driver of heart failure management. Higher filling pressures were often tolerated as “the cost of doing business” to support cardiac output. Over time, we recognized that systemic vascular resistance (SVR)—and its modulation via vasodilators—plays a significant role in improving forward flow. Today, the right ventricle (RV) has rightfully gained prominence.

• Forward flow: The effective delivery of blood from the heart into systemic circulation under optimal SVR and arterial pressure.
• Backward flow (congestion): The accumulation of pressure and volume in the venous system that reflects impaired forward capacity, manifesting as organ edema and rising venous pressures.
• Why the RV matters: The RV is the priming pump for the left ventricle. It modulates systemic venous return and pulmonary flow. When RV function is compromised, or the RV is subjected to high afterload (e.g., pulmonary hypertension), venous congestion intensifies, and forward flow suffers.

Modern management blends preload reduction (diuresis), afterload reduction (vasodilators), and RV optimization while monitoring filling pressures and cardiac output via echocardiography and, when indicated, catheter-based hemodynamics (Konstam et al., 2023; Nohria et al., 2003).

Venous Congestion, Abdominal Edema, and Venorenal Physiology

Many clinicians think first of ankle edema. In reality, the body often sequesters excess fluid in the splanchnic venous reservoir (liver, spleen, omentum, mesenteric vasculature) long before peripheral edema appears. In patients with advanced heart failure, we frequently see extensive abdominal congestion—not ascites—manifesting as abdominal wall edema, visceral swelling, and engorged splanchnic vessels. Echocardiography shows a plump inferior vena cava (IVC) with reduced inspiratory collapse, indicating elevated right-sided filling pressures and increased effective circulating volume.

This has direct consequences for the kidneys. The kidneys function on a pressure gradient: high glomerular capillary hydrostatic pressure and low post-glomerular venous pressure drive filtration. When renal venous pressure rises—due to systemic venous congestion—the effective gradient narrows, reducing glomerular filtration and impairing renal function, even with adequate arterial inflow. This is the essence of the venorenal state, in which venous pressures are central to the pathophysiology (Damman et al., 2014). Decongestion is not optional; it is essential to restore the gradient that allows the kidneys to filter.

The Power of Physical Assessment: Listening to the Patient’s Story

A thorough physical assessment is just as important as our diagnostic tests. Really honing in on the patient’s functional status and specific symptoms provides a real-world context for their lab and imaging results.

The New York Heart Association (NYHA) Functional Classification

This classification system is a cornerstone of heart failure assessment. It categorizes patients based on how their symptoms limit their physical activity.

• Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea.
• Class II: Slight limitation of physical activity. Comfortable at rest, but more-than-normal activity results in symptoms.
• Class III: Marked limitation of physical activity. Comfortable at rest, but less-than-ordinary activity causes symptoms.
• Class IV: Inability to carry on any physical activity without discomfort. Symptoms are present even at rest.

Key Signs and Symptoms of Congestion and Malperfusion

I ask specific, targeted questions to uncover subtle but critical signs of fluid overload and poor perfusion.

• Orthopnea: Shortness of breath when lying flat. I ask, “How many pillows do you sleep on?” or “Are you even sleeping in your bed anymore?” Many patients with severe orthopnea have moved to a recliner.
• Paroxysmal Nocturnal Dyspnea (PND): A sudden awakening at night with severe breathlessness. I’ve learned that patients often identify this as a “nighttime panic attack.” I now specifically ask, “Do you ever wake up suddenly at night feeling like you can’t breathe, or like you’re having a panic attack in your sleep?”
• Bendopnea: The term literally means “shortness of breath upon bending over.” I’ve witnessed this in the clinic: a patient bends down to tie their shoe and then has to sit up to catch their breath. It’s a very specific sign of elevated cardiac filling pressures.
• Dyspnea on Exertion (DOE): To get an accurate picture, I frame my questions around daily functional activities: “Can you walk across the Walmart parking lot without stopping?” “Can you push a vacuum cleaner?”
• Abdominal Findings: Clinically, I palpate for hepatosplenomegaly, assess ascites, evaluate jugular venous distention, and look for hepatojugular reflux. These findings of central volume overload often precede lower-extremity edema. Patients report abdominal tightness, early satiety, and worsening dyspnea—signals of systemic venous hypertension.

The Initial Diagnostic Workup: Uncovering the Story

When a patient presents with symptoms like dyspnea, my first step is to assemble a complete diagnostic picture with foundational laboratory tests.

• Complete Blood Count (CBC): To rule out other causes of dyspnea, such as anemia.
• Comprehensive Metabolic Panel (CMP): I always opt for a CMP over a Basic Metabolic Panel (BMP) because it includes liver function tests (AST, ALT, bilirubin). The liver and kidneys are what I call “ride or die friends”—when there’s significant systemic congestion affecting the kidneys, it almost invariably impacts the liver, causing “congestive hepatopathy.”
• B-type Natriuretic Peptide (BNP or pro-BNP): This is a critical biomarker for heart failure, released by the ventricles in response to being stretched by fluid overload.
• Lactate: An elevated lactate level is a fundamental indicator of poor perfusion. It helps me risk-stratify patients and answer a critical question: Is this patient simply congested, or is this patient congested and malperfusing? A high lactate signals the need for more aggressive intervention.
• Troponin: To assess for myocardial injury. An extreme elevation could point to an acute MI as the trigger for decompensation.
• Urinalysis and Urine Microalbumin: I am looking for protein. Gross proteinuria might suggest a chronic kidney process, while a urine microalbumin test can detect the earliest signs of diabetic or hypertensive kidney damage.

Essential Imaging and Electrical Assessments

• Echocardiogram (“Echo” ): An ultrasound of the heart that provides invaluable information about its structure and function, including the ejection fraction (EF) and right ventricular (RV) function.
• Renal Ultrasound: When a patient presents with a potential acute kidney injury (AKI), we must rule out a post-obstructive process by looking for hydronephrosis (swelling of the kidneys due to urine backup).
• 12-Lead EKG: Essential for looking for signs of ischemia or new arrhythmias like atrial fibrillation (A-Fib) that could trigger decompensation.

Hemodynamic Profiles and Cardiorenal Syndrome Phenotypes

Based on these findings, we can classify patients into hemodynamic profiles to guide therapy:

• Warm and Wet: Good perfusion (warm) but congested (wet). These patients primarily need diuretics.
• Cold and Wet: Poor perfusion (cold) and congested (wet). These patients need diuretics and may also need inotropes or other support to improve perfusion.
• Warm and Dry: Good perfusion but dehydrated.
• Cold and Dry: Poor perfusion but dehydrated.

The interplay between the heart and kidneys is further classified into five phenotypes of cardiorenal syndrome (Ronco et al., 2010):

1. Type 1: Acute heart failure leads to acute kidney injury.
2. Type 2: Chronic heart failure leads to progressive chronic kidney disease.
3. Type 3: Acute kidney injury leads to acute heart failure.
4. Type 4: Chronic kidney disease leads to cardiac dysfunction and heart failure.
5. Type 5: A systemic illness (like sepsis) causes both heart and kidney dysfunction simultaneously.

The Cornerstone of Treatment: Diuretic Therapy

When we manage patients with fluid overload, diuretic therapy is the cornerstone of our approach. However, loop diuretics, in particular, trigger the Renin-Angiotensin-Aldosterone System (RAAS), which can sometimes complicate treatment.

Diuretic Pharmacology: Understanding Threshold and Ceiling

To use diuretics effectively, we must understand two key concepts: threshold and ceiling.

• Threshold: The minimum concentration needed to produce an effect. Renal impairment and severe edema raise the threshold, meaning a higher initial dose is needed.
• Ceiling: The maximum effective dose. Beyond this point, increasing the dose only increases side effects. Once we reach the ceiling, we need to add another class of diuretics to achieve sequential nephron blockade.

Loop Diuretics: A Closer Look

The three most common loop diuretics are Furosemide (Lasix), Torsemide (Demadex), and Bumetanide (Bumex). Their oral dose equivalencies are key:

40 mg of furosemide = 20 mg of torsemide = 1 mg of bumetanide

The most telling factor is bioavailability. Oral furosemide has a notoriously unpredictable bioavailability (10-100%). For this reason, in my own practice, I have largely stopped using oral furosemide. I almost exclusively prescribe torsemide or bumetanide, which have a consistent bioavailability of 80-100%.

The half-life also dictates our dosing strategy. A drug with a short half-life like bumetanide should be dosed at least twice daily to ensure a consistent effect. A major pet peeve of mine is seeing diuretics scheduled late in the evening in the hospital, as this disrupts sleep and increases the risk of falls.

Navigating Diuretic Resistance and Renal Function

• Permissive Hypercreatininemia: It is very common for creatinine to rise after initiating aggressive diuresis. An increase of up to 0.5 mg/dL is often an expected consequence of RAAS activation. Panicking and stopping diuretics is often the worst thing to do.
• Sequential Nephron Blockade: If you’ve reached the ceiling dose of a loop diuretic and the patient is still not responding, it’s time to add a thiazide diuretic (like metolazone) or acetazolamide. This strategy blocks sodium reabsorption at multiple points in the nephron, producing a powerful synergistic effect (Mullens et al., 2019).

Beating the Odds: “Conquering Congestive Heart Failure”- Video

Guideline-Directed Medical Therapy (GDMT) with Renal Considerations

For patients with heart failure, optimizing cardiac function is the best way to support their kidneys. We must prioritize starting and titrating Guideline-Directed Medical Therapy (GDMT) even while they are congested.

• ACE inhibitors/ARBs/ARNI (sacubitril/valsartan): Reduce angiotensin II-mediated vasoconstriction and remodeling; ARNI also augments natriuretic peptide signaling. Titrate with renal monitoring.
• Beta-blockers: Temper sympathetic overdrive. However, if a patient is severely fluid overloaded and has never been on a beta-blocker, today is not the day to start one. We need to get some of the fluid off first.
• Mineralocorticoid receptor antagonists (MRAs): Block aldosterone, limiting fibrosis. Watch for hyperkalemia in CKD.
• SGLT2 inhibitors: Enhance glycosuria and natriuresis, reduce heart failure hospitalization, and confer reno-protection. They are beneficial even in patients with non-diabetic heart failure (Packer et al., 2020).
• Iron repletion (IV iron for iron deficiency): Improves exercise capacity and quality of life in heart failure.

Advanced Therapies for Refractory Cases

When a patient has refractory oliguria (low urine output) despite optimal diuretic therapy, it’s time to consider inotropes like dobutamine or milrinone to increase the heart’s contractility. When all medical therapies fail, we turn to ultrafiltration (mechanical fluid removal) with our nephrology colleagues or, in the most severe cases, to mechanical circulatory support (MCS), such as Impella or ECMO.

The Role of Integrative Chiropractic Care in Cardiorenal Management

Understanding these complex interactions is where our integrative model at Injury Medical Clinic truly shines. Chiropractic care is not a substitute for cardiology or nephrology, but it is a valuable adjunct that addresses musculoskeletal and autonomic factors impacting hemodynamics and symptom burden.

• Improving Neuromechanical Function and Thoracic Mobility: Through chiropractic adjustments, we can improve joint mobility, particularly in the thoracic spine and rib cage. This can enhance chest wall expansion, improve ventilatory efficiency, ease the mechanical work of breathing, and improve venous return via the respiratory pump.
• Managing Musculoskeletal Compensation: Systemic issues such as fluid overload and fatigue can lead to changes in posture, gait, and mobility. We address these compensatory patterns, which can strain the hips, knees, and lower back.
• Rehabilitation and Functional Movement: Under the medical supervision of Dr. Cardenas, we design gentle, progressive exercise programs to activate the skeletal muscle pump in the legs, helping return fluid and reduce peripheral edema.
• Autonomic Modulation: Gentle spinal mobilization and soft-tissue work can influence autonomic tone, reducing sympathetic overdrive that exacerbates vasoconstriction and fluid retention. This can facilitate autonomic balance and improve baroreflex sensitivity.
• Postural Interventions: Kyphosis and forward head posture can impair diaphragmatic excursion and limit splanchnic venous outflow. Corrective exercises optimize biomechanics and the respiratory pump.

All chiropractic interventions are planned in coordination with Dr. Cardenas’s medical assessments, taking into account ejection fraction, RV function, blood pressure stability, and volume status.

Functional Medicine Lens: Modulating Inflammation and Metabolic Stress

Our functional medicine approach provides adjunctive benefits by addressing the root causes of inflammation and metabolic dysfunction that often underlie both heart and kidney disease.

• Nutrition: Sodium awareness tailored to individual diuretic response; emphasis on potassium/magnesium intake; and anti-inflammatory diet patterns to support endothelial function.
• Glycemic control: Stabilizing blood glucose protects microvasculature.
• Micronutrient repletion: Address iron deficiency, vitamin D, and cofactors for mitochondrial efficiency.
• Gut health: Manage dysbiosis associated with gut wall edema from congestion.
• Sleep optimization: Evaluate for sleep-disordered breathing; improved oxygenation supports heart and kidney resilience.
• Stress physiology: HRV-guided breathing and mindfulness to reduce sympathetic burden.

Closing Thoughts: Treating the System, Not Just Symptoms

Cardiorenal syndrome challenges us to think beyond single-organ frameworks. By integrating internal medicine oversight, chiropractic biomechanics, functional medicine, and rehabilitation, we create a pathway in which therapies support one another rather than compete. In our El Paso practice, this is not theoretical—it’s the daily logic we apply to real patients, with meaningful improvements in function, comfort, and resilience. From my clinical observations and shared insights via my platforms (see dralexjimenez.com; LinkedIn: Dr. Alex Jimenez), patients with combined heart-kidney vulnerability benefit most when care is congestion-centered, autonomically aware, and data-driven.

This educational content is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional for any health concerns or before making any decisions about your health or treatment.

References

• Bauersachs, J., & Zannad, F. (2014). Heart failure drug treatment: The fantastic four. European Heart Journal, 35(48), 2904–2915.
• Damman, K., van Deursen, V. M., Navis, G., Voors, A. A., van Veldhuisen, D. J., & Hillege, H. L. (2014). Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. European Heart Journal, 35(7), 455–469.
• Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Tang, W. H. W., O’Connor, C. M., & DOSE Trial Group. (2011). Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine, 364(9), 797–805.
• Konstam, M. A., Kiernan, M. S., Bernstein, D., et al. (2023). Evaluation and management of right heart failure: a scientific statement from the American Heart Association. Circulation, 147(15), e673–e702.
• Mann, D. L., & Bristow, M. R. (2005). Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation, 111(25), 2837–2849.
• McMurray, J. J. V., et al. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. NEJM, 371(11), 993–1004.
• Mullens, W., et al. (2019). The use of diuretics in heart failure with congestion: A position statement. European Journal of Heart Failure, 21(2), 137–155.
• Nolan, R. P., et al. (2018). Heart rate variability biofeedback as a complementary therapy in heart failure. Applied Psychophysiology and Biofeedback, 43(3), 155–167.
• Nohria, A., Tsang, S. W., Fang, J. C., et al. (2003). Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. Journal of the American College of Cardiology, 41(10), 1797–1804.
• Packer, M., et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. NEJM, 383(15), 1413–1424.
• Ronco, C., McCullough, P. A., Anker, S. D., et al. (2010). Cardio-Renal Syndromes: Report from the Consensus Conference of the Acute Dialysis Quality Initiative. Journal of the American College of Cardiology, 55(11), 1139–1152.
• Solomon, S. D., et al. (2019). Sacubitril/valsartan across the spectrum of ejection fraction. JACC, 74(25), 3205–3217.
• Volpe, M., et al. (2015). Natriuretic peptides and cardio-renal protection. International Journal of Cardiology, 212, 265–271.
• Yancy, C. W., et al. (2013). 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128(16), e240–e327.

SEO tags: Cardiorenal Syndrome, Integrative Chiropractic Care, Heart Failure, Kidney Disease, Dr. Alex Jimenez, El Paso Chiropractor, Functional Medicine, Dyspnea, Acute Kidney Injury, Dr. Maria Cardenas, Multidisciplinary Clinic, NYHA Classification, Bendopnea, Paroxysmal Nocturnal Dyspnea, Fluid Overload, Diuretic Therapy, Furosemide, Torsemide, RAAS, SGLT2 inhibitors, venous congestion, right ventricle function, Malperfusion, Personal Injury Care, Rehabilitation, autonomic balance, HRV